![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif)
New Antiepileptic Drugs
Into the New Millennium
William O. Tatum, IV, DO;
Rupert Galvez, BA;
Selim Benbadis, MD;
Enrique Carrazana, MD
Arch Fam Med. 2000;9:1135-1141.
There has been an explosion of new antiepileptic drug availability for physicians to treat patients with recurrent seizures. Principal antiepileptic drugs consisted of 6 key agents for both generalized and partial epilepsy for nearly 8 decades. Since 1993, the availability of newer "second-generation" agents has nearly doubled the armamentarium available for the 2.5 million patients who have recurrent seizures. This new influx of medications has flooded the medical and lay community with choices never before appreciated. The promise of improved tolerability with different safety and efficacy profiles has been exciting for all involved in epilepsy management. While most of the newer agents have been approved for adjunctive use in medically refractory partial epilepsy with recurrent complex partial and secondarily generalized seizures, efficacy is expanding to include generalized epilepsy and children for some agents.
From the Department of Neurology (Dr Tatum), Epilepsy Center and the Department of Neurology and Neurosurgery (Dr Benbadis), Tampa General Hospital, University of South Florida, Tampa (Drs Tatum and Benbadis and Mr Galvez), and the Department of Neurology, Baptist Medical Center, University of Miami, Miami, Fla (Dr Carrazana).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Updates on the Treatment of Epilepsy in Women
Tatum et al.
Arch Intern Med 2004;164:137-145.
ABSTRACT
| FULL TEXT
|